Physician profile
Jacob M Estes
NPI 1255381687
$16,431.73
in general payments reported to CMS, 2019-2025
12 companies · $13K in 2025
The $13K reported for 2025 was more than what 93% of Gynecologic Oncology providers received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $571 · 2020: $642 · 2021: $844 · 2022: $301 · 2023: $287 · 2024: $347 · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $13K · Food and Beverage: $1,573.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $12,500.00 |
| Food and Beverage | $1,572.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dilon Technologies, INC. | $8,286.21 | 2023-2025 | Hemoblast Bellows |
| Evologics LLC | $5,000.00 | 2025 | |
| Biom'Up France Sas | $1,141.63 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $769.17 | 2019-2025 | Keytruda, Lynparza |
| Eisai INC. | $308.85 | 2021-2022 | |
| Biom'Up Sa | $255.76 | 2019 | |
| Myriad Genetic Laboratories, INC. | $137.50 | 2022 | |
| Tesaro, INC. | $127.73 | 2019 | |
| Clovis Oncology, INC. | $125.00 | 2019 | |
| Glaxosmithkline, LLC. | $123.61 | 2023-2025 | Jemperli, Zejula |
| Abbvie INC. | $111.60 | 2024-2025 | |
| Gen-Probe Sales & Service, INC. | $44.67 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacob Estes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.